4//SEC Filing
Mahoney Stephen F. 4
Accession 0001104659-18-036484
CIK 0001730430other
Filed
May 28, 8:00 PM ET
Accepted
May 29, 7:18 PM ET
Size
15.0 KB
Accession
0001104659-18-036484
Insider Transaction Report
Form 4
Mahoney Stephen F.
President & COO10% Owner
Transactions
- Purchase
Series C Preferred Shares
2018-02-09$15.64/sh+6,392$99,995→ 6,392 total→ Class A Common Shares (6,392 underlying) - Conversion
Series C Preferred Shares
2018-05-29−6,392→ 0 total→ Class A Common Shares (6,392 underlying) - Conversion
Class A Common Shares
2018-05-29+6,392→ 79,589 total - Conversion
Series A Preferred Shares
2018-05-29−107,050→ 0 total→ Class B Common Shares (107,050 underlying) - Conversion
Class B Common Shares
2018-05-29+107,050→ 656,027 total→ Class A Common Shares (107,050 underlying)
Holdings
- 36,598(indirect: By Trust)
Class A Common Shares
Footnotes (4)
- [F1]Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.
- [F2]Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.
- [F3]Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.
- [F4]Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.
Documents
Issuer
Kiniksa Pharmaceuticals, Ltd.
CIK 0001730430
Entity typeother
Related Parties
1- filerCIK 0001741389
Filing Metadata
- Form type
- 4
- Filed
- May 28, 8:00 PM ET
- Accepted
- May 29, 7:18 PM ET
- Size
- 15.0 KB